Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P04179 (MnSOD)
 2,777 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To elucidate the interactions of catechins with the cellular antioxidative system, human hepatoma HepG2 cells were incubated in a serum-free medium with catechins, and the level of thiobarbituric acid-reactive substances (TBARS) as a marker of lipid peroxidation was determined, as well as the contents of alpha-tocopherol (alpha-Toc) and glutathione (GSH) and the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px). TBARS was promptly decreased by the incubation with epigallocatechin 3-O-gallate (EGCG), and 12h later TBARS in the cells with 10microM EGCG was about 15% (p < 0.05) of that in the controls (without catechins). Epigallocatechin, epicatechin 3-O-gallate, and epicatechin also had an antioxidative activity, but a higher concentration was required to induce the same effect as EGCG. In the cells incubated with EGCG, the consumption of alpha-Toc and the formation of the oxidized form of GSH were suppressed. Although EGCG showed no effects on the Cu/Zn-SOD activity, the Mn-SOD activity in the cells was enhanced (p < 0.05) by the incubation with EGCG. Moreover, the GSH-Px activity was maintained at a higher level (p < 0.05) in the cells with EGCG, compared with that in the controls. When the cells were preincubated with EGCG, the cytotoxicity of H2O2 was significantly reduced. Furthermore, the decrease of cellular alpha-Toc content induced by exposure to H2O2 was prevented by the pretreatment of EGCG. These results suggest that EGCG taken up into HepG2 cells is preferentially used as an antioxidant, rather than alpha-Toc and GSH, to suppress lipid peroxidation and to protect these cells from oxidative damages.
 ...
PMID:Effects of epigallocatechin 3-O-gallate on cellular antioxidative system in HepG2 cells. 1217 41

Cisplatin nephropathy can be regarded as a mitochondrial disease. Intervention to halt such deleterious injury is under investigation. Recently, the flavanol (-)-epicatechin emerges as a novel compound to protect the cardiovascular system, owing in part to mitochondrial protection. Here, we have hypothesized that epicatechin prevents the progression of cisplatin-induced kidney injury by protecting mitochondria. Epicatechin was administered 8 h after cisplatin injury was induced in the mouse kidney. Cisplatin significantly induced renal dysfunction and tubular injury along with an increase in oxidative stress. Mitochondrial damages were also evident as a decrease in loss of mitochondrial mass with a reduction in the oxidative phosphorylation complexes and low levels of MnSOD. The renal damages and mitochondrial injuries were significantly prevented by epicatechin treatment. Consistent with these observations, an in vitro study using cultured mouse proximal tubular cells demonstrated that cisplatin-induced mitochondrial injury, as revealed by a decrease in mitochondrial succinate dehydrogenase activity, an induction of cytochrome c release, mitochondrial fragmentation, and a reduction in complex IV protein, was prevented by epicatechin. Such a protective effect of epicatechin might be attributed to decreased oxidative stress and reduced ERK activity. Finally, we confirmed that epicatechin did not perturb the anticancer effect of cisplatin in HeLa cells. In conclusion, epicatechin exhibits protective effects due in part to its ability to prevent the progression of mitochondrial injury in mouse cisplatin nephropathy. Epicatechin may be a novel option to treat renal disorders associated with mitochondrial dysfunction.
 ...
PMID:Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy. 2293 2